Urological malignancies in kidney transplant recipient patients
DOI:
https://doi.org/10.52786/isu.a.77Keywords:
Renal transplant, renal cell carcinoma, urothelial carcinoma, urological malignancyAbstract
Kidney transplantation is now established as the ideal treatment option for end-stage renal disease (ESRD) and renal cell carcinoma (RCC) patients. Since the first kidney transplant in the 1970s, research has allowed us to understand the long term sequelae of kidney transplant patients (TXPs) including the risks of increased malignancy from immunosuppression.
References
Woo KT. Perspectives of end stage renal failure therapy in Singapore. Ann Acad Med Singap 1993; 22:393-400.
Soh P, Lim SM, Tan EC. Organ procurement in Singapore. Ann Acad Med Singap 1991;20:439-42.
Annual Report. Singapore: NRDO; 2021. Singapore Renal Registry Report.
Shern TKY. Renal transplantation at the Singapore General Hospital: a miracle in the making over 50 years. Proceedings of Singapore Healthcare. 2020; 29:245-51.
Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011;11:2093-109.
Chaudhry D, Chaudhry A, Peracha J, Sharif A. Survival for waitlisted kidney failure patients receiving transaplantation versus remaining on waiting list: systematic review and meta-analysis. BMJ 2022;37:e068769.
Au E, Wong G, Chapman JR. Cancer in kidney transplant recipients. Nat Rev Nephrol 2018;14:508-20.
Dahle DO, Skauby M, Langberg CW, Brabrand K, Wessel N, Midtvedt K. Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review. Transplantation 2022;106:e52-63.
Goh A, Vathsala A. Native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients. Am J Transplant 2011;11:86-92.
Watschinger B, Budde K, Crepo M, Heemann U, Hilbrands L, Maggiore U. Pre-existing malignancies in renal transplant candidates-time to reconsider waiting times. Nephrol Dial Transplant 2019;34:1292-1300.
Boissier R, Hevia V, Bruins HM, BuddeK, Figueiredo A, Lledó-García E, et al. The risk of tumour recurrence in patients undergoing renal transplantation for end-stage renal disease after previous treatment for a urological cancer: a systematic review. Eur Urol 2018;73:94-108.
Tsaur I, Karalis A, Probst M, Blaheta RA, Scheuermann EH, Gossmann J, et al. Development of urological cancers in renal transplant recipients: 30-year experience at the Frankfurt Transplant Center. Cancer Sci 2010;101:2430-5.
Abbas M, Pätzel M, Thurn A, Brinkmann OA, Bettendorf O. Incidental occurrence of papillary renal cell carcinoma in the native kidney with autosomal dominant polycystic kidney disease after renal transplantation: a case report. Mol Clin Oncol 2021;15:223.
Klatte T, Marberger M. Renal cell carcinoma of native kidneys in renal transplant patients. Curr Opin Urol 2011;21:376-9.
Demetrios M, Kiriaki K, Chrysoula A, Nikolaos G, John B, Spyridon V, et al. Renal cell carcinoma of native kidneys in renal transplant recipients: a single-center experience. Anticancer Res 2017;37:773.
Jarzemski P, Listopadzki S, Słupski P, Jarzemski M, Brzoszczyk B. Simultaneous bilateral native nephrectomy by retroperitoneal approach. Int Braz J Urol 2020;46:538-44.
Park KH, Yoon JA, Kim HS, Kim H, Park SK, Kim YH, et al. Clinical features and outcomes in kidney transplant recipients with renal cell carcinoma: a single-center study. Kidney Res Clin Pract 2019;38:517-24.
European Renal Best Practice Transplantation Guideline Development Group. ERBP Guideline on the Management and Evaluation of the Kidney Donor and Recipient. Nephrol Dial Transplant 2013;28:ii1-71.
Ljungberg B, Albiges L, Bedke J, Bex A, Capitanio U, Giles RH, et al. EAU Guidelines on Renal Cell Carcinoma [Internet]. [cited 2023 July 15]:1-99. Available from: https://d56bochluxqnz.cloud-front.net/documents/full-guideline/EAU-Guide- lines-on-Renal-Cell-Carcinoma-2023.pdf
Lu J, Tay HW, Wu MW, Rahman L, Tiong HY. Out- comes of radical nephrectomyfor end stage renal failure (ESRF) patients with renal Cell carcinoma (RCC) Abstracts. BJU International 2014;113:1-37.
Chen K, Huang HH, Aydin H, Tan YH, Lau WK, Cheng CW, Yuen JS. Renal cell carcinoma in patients with end-stage renal disease is associated with more favourable histological features and prognosis. Scand J Urol 2015;49:200-4.
Graves A, Hessamodini H, Wong G, Lim WH. Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther 2013;2:73-90.
Griffith JJ, Amin KA, Waingankar N, Lerner SM, Delaney V, Ames SA, et al. Solid Renal Masses in Transplanted Allograft Kidneys: A Closer Look at the Epidemiology and Management. Am J Transplant 2017;17:2775-81.
O’Connor E, Timm B, Lawrentschuk N, Ischia J. Open partial nephrectomy: current review. Transl Androl Urol 2020;9:3149-59.
Zhao H, Alam A, Soo AP, George AJT, Ma D. Ischemia-reperfusion injury reduces long term renal graft survival: mechanism and beyond. EBio Medicine 2018;28:31-42.
Battelli C, Cho DC. mTOR inhibitors in renal cell carcinoma. Therapy 2011;8:359-67.
Cuadrado-Payán E, Diekmann F, Cucchiari D. Medical Aspects of mTOR Inhibition in Kidney Transplantation. Int J Mol Sci 2022;23:7707.
Bermejo S, Bolufer M, Riveiro-Barciela M, Soler MJ. Immunotherapy and the spectrum of kidney disease: should we individualize the treatment? Front Med (Lausanne) 2022;9:906565.
Ardelt PU, Rieken M, Ebbing J, Bonkat G, Vlajnic T, Bubendorf L, et al. Urothelial cancer in renal transplant recipients: incidence, risk factors, and oncological outcome. Urology 2016;88:104-10.
Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823-31.
Hickman LA, Sawinski D, Guzzo T, Locke JE. Urologic malignancies in kidney transplantation. Am J Transplant 2018;18:13-22.
Wang Y, Lan G, Peng F, Xie X. Cancer risks in recip- ients of renal transplants: a meta-analysis of cohort studies. Oncotarget 2018;9:15375-85.
Hosain GMM, Khan MM, Amiel GE, Lerner SP, Latini DM, Chen GJ. Racial/Ethnic Differences in Upper-Tract Urothelial Cancer. Rthn Dis 2012;22:295-301.
Miao Y, Everly JJ, Gross TG, Tevar AD, First MR, Alloway RR, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009;87:1347-59.
Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA 2006;296:2823-31.
Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A 2012;109:8241-6.
Liu S, Chaudhry MR, Berrebi AA, Papadimitriou JC, Drachenberg CB, Haririan A, et al. Polyomavirus replication and smoking are independent risk factors for bladder cancer after renal transplantation. Transplantation 2017;101:1488-94.
van Aalderen MC, Heutinck KM, Huisman C, ten Berge IJ. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. Neth J Med 2012;70:172-83.
Viswesh V, Yost SE, Kaplan B. The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: A systematic review. Transplant Rev (Orlando) 2015;29:175-80.
Wang Y, Yan S, Liu Y, Yan Z, Deng W, Geng J, et al. Dynamic viral integration patterns actively participate in the progression of BK polyomavirus-as- sociated diseases after renal transplantation. Am J Transplant 2023;23:1694-1708.
Ortega RMM, Wolff DJ, Schandl CA, Drabkin HA. Urothelial carcinoma of donor origin in a kidney transplant patient. J Immunother Cancer 2016;4:63.
Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the national cancer database, 2003 to 2007. J Urol 2011;185:72-8.
Tsaur I, Karalis A, Blaheta R, Juenge E, Vallo S, Probst M, et al. Transitional cell carcinoma of the native urinary tract after kidney transplantation: recommendations following a long-term retrospective analysis. Am J Med Sci 2011;341:478-83,
Jiang S, Redelman-Sidi G. BCG in Bladder cancer immunotherapy. Cancers (Basel) 2022;14:3073.
Prabharasuth D, Moses KA, Bernstein M, Dalbagni G, Herr HW. Management of bladder cancer after renal transplantation. Urology 2013;81:813-9.
Deresiewicz RL, Stone RM, Aster JC. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. J Urol 1990;144:1331-3; discussion 1333-4.
Palou J, Angerri O, Segarra J, Caparrós J, Guirado L, Diaz JM, et al. Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 2003;76:1514-6.
Tomaszewski JJ, Larson JA, Smaldone MC, Hayn MH, Jackman SV. Management of Bladder Cancer following Solid Organ Transplantation. Adv Urol 2011;2011:256985.
Herr HW, Dalbagni G. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer. BJU Int 2013;111:984-7.
Rouprêt M, Gontero P, Birtle A, Compérat EM, Dominguez-Escrig JL, Liedberg F, et al. EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma [Internet]. 2023 [cited 2023 July 15]:1-44. Available from: https://d56bochluxqnz.cloudfront.net/ documents/full-guideline/EAU-Guidelines-on-Up- per-Urinary-Tract-Urothelial-Carcinoma-2023.pdf
Olsburgh J, Zakri R, Horsfield C, Collins R, Fairweather J, O’Donnell P, Koffman G. TCC in transplant ureter-When and When not to preserve the transplant kidney. Am J Transplant 2016;16:704-11.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Insight Urology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
